Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Date:9/11/2012

CRANBURY, N.J., Sept. 11, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012. 

Fiscal Year and Recent Highlights

  • Bremelanotide development for Female Sexual Dysfunction (FSD):
  • Palatin completed patient treatment in its Phase 2B clinical trial in premenopausal women with FSD
  • Primary data analysis and announcement of top-line results anticipated in first-half of fourth quarter of calendar year 2012
  • Obesity Collaboration with AstraZeneca:
  • Multiple classes of collaboration compounds have advanced to various stages of development. Though collaboration partner AstraZeneca has decided to discontinue further development of AZD2820, the only compound in clinical trials, AstraZeneca remains committed to this collaboration program and to the continued advancement of collaboration compounds for treatment of obesity.
  • Intellectual property developments:
  • Two additional United States patents have issued in the melanocortin field
  • Palatin has advanced its bremelanotide, PL-3994, and new melanocortin peptide patent applications in countries outside the United States
  • Equity financing:
  • On July 3, 2012, Palatin closed on a $35.0 million private placement.  The offering consisted of the sale of 3,873,000 shares of common stock, Series A 2012 warrants to purchase 31,988,151 shares of common stock, and Series B 2012 warrants to purchase 35,488,380 shares of common stock.
  • Net proceeds to Palatin after deducting offering expenses were $34.5 million 
  • Fourth Quarter and Fiscal Year End 2012 ResultsPalatin reported a net loss of $5.3 million, or $(0.14) per basic and diluted share
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
    2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
    5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
    6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
    7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
    8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
    9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
    10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
    11. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/20/2014)... time, chemists have succeeded in measuring vibrational motion of ... study reveals how vibration of a single molecule differs ... The study was performed at the University of California, ... of Jyvskyl works as a visiting fellow under professor ... The second team was lead by Professor Eric O. ...
    (Date:8/20/2014)... -- PAREXEL International Corporation (NASDAQ: PRXL ) announced ... Healthcare Conference in New York.  Ingo Bank , ... making a presentation on PAREXEL and discussing business developments ... A live webcast of the discussion will ... at www.PAREXEL.com in the Upcoming Events portion ...
    (Date:8/20/2014)... nerves in your ear could improve the health of ... the University of Leeds used a standard TENS machine ... electrical pulses to the tragus, the small raised flap ... of the ear canal. , The stimulation changed the ... reducing the nervous signals that can drive failing hearts ...
    (Date:8/19/2014)... 2014 Shimadzu Scientific Instruments has ... and Nexera-i, adding to the company’s extensive line-up ... an intuitive operating environment, and full automation, the ... workflow for conventional to ultra-high-speed analysis. ... intelligent design so users can begin building the ...
    Breaking Biology Technology:Seeing a molecule breathe 2PAREXEL International To Present At Baird Healthcare Conference 2'Tickling' your ear could be good for your heart 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3
    ... 13, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
    ... sunscreens when they are exposed to sunlight? And how is ... has been the subject of research at the University of ... at the upcoming dermatologist conference in Gothenburg. A growing ... habits have brought an increase in the number of cases ...
    ... Beta-Pro LLC, announced today that it has ... pharmaceutical drug discovery and research institutes in the ... company now manages extensive laboratory facilities in the ...   "Beta-Pro has already established a ...
    Cached Biology Technology:Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 2Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 3Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 4Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 5Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 6Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 7Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 8Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco 9So that's why we're allergic to sun creams 2Beta-Pro Expands Operations to Meet Demands for Human Cells in Hepatocyte Drug Discovery Market 2
    (Date:8/20/2014)... salty aroma of sunscreen and seawater signals a relaxing ... that the idyllic beach vacation comes with an environmental ... into the sea, they can become toxic to some ... course for many other marine animals. Their study appears ... . , Antonio Tovar-Sanchez and David Snchez-Quiles point out ...
    (Date:8/20/2014)... A new gene therapy developed by researchers at the ... to protect mice from a life-threatening heart condition caused ... therapeutic avenue," said Yi Lai, Ph.D., the leading author ... MU School of Medicine,s Department of Molecular Microbiology and ... hope this could lead to a treatment for people ...
    (Date:8/20/2014)... DENVER , Aug. 20, 2014  The ... take place in Tampa, Florida ... interactive sessions with Steven Rahman, Director, Technology and Strategy ... Sector at Experian. The theme of this year,s ... and Privacy. "Biometrics UnPlugged: Mobility ...
    Breaking Biology News(10 mins):Gene therapy protects mice from lethal heart condition, MU researchers find 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
    ... Athens, Ga. For more than a century, the ... it comes to human health. As it turns out, X-rays ... and a new approach -- just published by researchers at ... can learn using the technique. One of the primary ...
    ... a recent study by the University of Santiago de Compostela ... unexpected increase in hydrocarbon levels along the coast of Galicia ... years by works to remove the wreck, pollution levels began ... numerous forest fires., On 19th November 2002 the oil tanker ...
    ... only become a science in the past 25 years, ... with widespread international collaboration, broad disciplinary composition and wide ... National Laboratory and Indiana University. The findings, published today ... Sciences, were assembled from a review of 20,000 ...
    Cached Biology News:New strategy could lead to dose reduction in X-ray imaging 2New strategy could lead to dose reduction in X-ray imaging 3Hydrocarbon pollution along the coast of Galicia shot up five years after the Prestige oil spill 2After 25 years, sustainability is a growing science that's here to stay 2
    ... At the forefront of Agilent analytical ... Built-in local area networking (LAN) allows you ... sites--for fast and informed decision making. Just ... has all the flexibility and performance needed ...
    ... Inc.'s CP-4900 is a rugged, ... delivers the information you need ... the composition of gas mixtures ... micro-Gas Chromatograph generates more data ...
    ... GC system combines world-class performance hardware, Cerity ... Agilents world-renowned support and columns, as well ... combination that lets you reach uncompromising results ... dependable data. The Agilent 6820 GC system ...
    ... Peroxisome Proliferator-Activated Receptor-gamma (PPARGamma) Competitor ... and efficient method for studying ... using fluorescence polarization (FP). The ... domain (PPARGamma-LBD) with an N-terminal ...
    Biology Products: